OA-570 - Effect of intermittent preventive treatment in school-age children on malaria incidence in above fifteen years old population in rural Burkina Faso
Speakers:
- Serge Henri Zango, Clinical Research Unit of Nanoro/ Research Institute for Health Sciences/ National Center for Scientific and Technological Research (URCN/IRSS/CNRST), Burkina Faso
OA-418 - Acceptability and feasibility of implementing perennial malaria chemoprevention integrated into EPI in Togo: lessons learned from the MULTIPLY project
Speakers:
- Rodion Konu, Faculty of Health Sciences, Department of Public Health, University of Lomé, Center for Training and Research in Public Health, Togo
OA-429 - Cost-effectiveness of perennial malaria chemoprevention in children under two years of age delivered alongside the expanded program on immunization in Sierra Leone, Togo and Mozambique
Speakers:
- Maria Martínez Domínguez, Barcelona Institute of Global Health (ISGlobal), Spain
OA-434 - Effects of dihydroartemisinin-piperaquine for malaria preventive treatment on antiretroviral drugs concentrations and associated factors in African pregnant women living with HIV
Speakers:
- Linda Stöger, Barcelona Institute for Global Health (ISGlobal), Spain
OA-384 - Acceptability of dihydroartemisinin-piperaquine as malaria intermittent preventive treatment for pregnant women living with HIV in Southern Mozambique
Speakers:
- Tacilta Nhampossa, Manhiça Health Research Center (CISM) and Manhiça Foundation, Mozambique
OA-709 - Strengthening health systems through implementation support strategies: evidence from Kapolowe District, DRC
Speakers:
- Tafadzwa Maseko, University of Antwerp, Belgium